Nobilus Ent
Nobilus Ent is a privately held Polish pharmaceutical manufacturer founded in 1990, operating two GMP/GDP-certified production divisions that manufacture active pharmaceutical ingredients (synthetic and plant-derived) and contract-manufacture non-sterile drug products for pharmaceutical-company clients.
- Company typePrivate
- Founded1990
- HeadquartersJabłonna, Poland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Nobilus Ent does
Nobilus Ent is a privately held Polish pharmaceutical manufacturer founded in 1990, operating as a B2B contract manufacturer of active pharmaceutical ingredients (APIs) and finished non-sterile drug products. The company operates two manufacturing divisions: the Jabłonna Division near Warsaw, which performs contract manufacturing of non-sterile drug products (hard capsules, liquid forms, and semi-solid forms) and handles distribution of active substances; and the Kutno Division, located in the Łódź Special Economic Zone, which manufactures APIs through chemical synthesis and isolation from plant materials (horse chestnut and wooly foxglove). The company serves pharmaceutical manufacturers seeking custom synthesis, encapsulation, specialized packaging, and contract manufacturing services, with both divisions maintaining GMP and GDP certifications and products meeting EP, USP, BP, JP, and ChP pharmacopeial standards.
The company's product portfolio spans three main categories: synthetic APIs (clozapine, flutamide, imatinib mesilate, iron dextran, mesna, and others), plant-derived APIs from horse chestnut (α-escin, β-escin, esculin) and wooly foxglove (digoxin, digitoxin, lanatoside C, and related cardiac glycosides), and impurity reference standards. A 2021-established Biotechnology Department at Kutno added microorganism cultivation capability up to 1,500 liters, expanding the technological platform into bioprocessing. The company also produces xanthohumol as a newer botanical API offering. All manufacturing technology is developed in-house, with dedicated R&D departments at both divisions focused on new API forms and process improvement.
Nobilus Ent generates revenue through B2B contract manufacturing agreements with pharmaceutical companies, with pricing negotiated on a contract basis depending on product specifications, volumes, and requirements. The company employs approximately 120 people across both divisions and distributes products directly through its GDP-certified distribution network. Marketing occurs primarily through the corporate website (nobilusent.pl), with direct email contact for contract manufacturing inquiries. The company has no disclosed external investors, parent company, or subsidiaries, and operates as an independent niche specialty pharmaceutical manufacturer in Poland.
Nobilus Ent firmographics
Firmographics- Name
- Nobilus Ent
- Legal name
- Nobilus Ent
- Website
- https://nobilusent.pl
- Company type
- Private
- Founded year
- 1990
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Nobilus Ent is a privately held Polish pharmaceutical manufacturer founded in 1990, operating two GMP/GDP-certified production divisions that manufacture active pharmaceutical ingredients (synthetic and plant-derived) and contract-manufacture non-sterile drug products for pharmaceutical-company clients.
- Ownership category
- akta.pro rank
Nobilus Ent industry classification
Industry- Product category
- Pharmaceutical Contract Manufacturing
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Small-Molecule API Commercial Manufacturing (HLAGAHAB)
- akta.pro secondary industries
- Small-Molecule API Process Development & Route Scouting (HLAGAHAA), Impurity / Reference Standard Synthesis & Characterization (HLAGAHAG), Drug Product Fill-Finish & Aseptic Manufacturing Services (HLAAAKAB)
Keywords
Where Nobilus Ent is headquartered
LocationHeadquarters
- HQ city
- Jabłonna
- HQ country
- Poland
- HQ region
- Europe
Offices2 records
Markets served
Nobilus Ent business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure
Revenue model
- Contract Manufacturing of APIs: Manufacturing of active pharmaceutical ingredients through synthesis or isolation from plant materials. Products include synthetic substances (Clozapine, Flutamide, Imatinib mesylate, Iron dextran, Dextranomer, Mesna, Diethylamine Salicylate, Glycine hydrochloride) and semi-synthetic substances from horse chestnut and wooly foxglove. Revenue is generated through B2B contracts with pharmaceutical companies.
- Contract Manufacturing of Finished Drug Products: Manufacturing of non-sterile drug products including hard capsules, liquid forms, and semi-solid forms for human usage. Services include custom synthesis, encapsulation, packaging according to customer requirements.
- Impurity Reference Standards: Production and distribution of digoxin-related impurity reference standards (Digitoxin, Gitoxin, Digoxigenin, Diginatin, Neodigoxin, Lanatoside C, Digoxigenin tetrakisdigitoxoside).
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Nobilus Ent product offering
Product offeringCore offering
Nobilus Ent manufactures active pharmaceutical ingredients (APIs) through synthesis and isolation from plant materials (horse chestnut and wooly foxglove), and performs contract manufacturing of non-sterile finished drug products (hard capsules, liquid forms, semi-solid forms). The company operates two GMP-certified divisions in Poland serving pharmaceutical companies with custom synthesis, encapsulation, specialized packaging, and impurity reference standards.
Product overview
Nobilus Ent is a Polish pharmaceutical manufacturer founded in 1990, operating two divisions: the Jabłonna Division (near Warsaw) performing contract manufacturing of non-sterile drug products (hard capsules, liquid and semi-solid forms), and the Kutno Division (in Łódź Special Economic Zone) manufacturing active pharmaceutical ingredients through synthesis and plant material extraction. The company produces horse chestnut-derived substances (α-escin, β-escin, esculin), wooly foxglove-derived cardiac glycosides (digoxin, digitoxin, lanatoside C), synthetic APIs (clozapine, flutamide, imatinib mesilate), impurity reference standards, and new products like xanthohumol. Both divisions maintain R&D departments for process improvement and new product development. All products meet GMP and pharmacopeial requirements (EP, USP, BP, JP, ChP).
Differentiator
Problem solved
Functional benefit
Products and services
- Horse Chestnut Extracts and Semi-synthetic Substances
Quantifiable outcome
- Products meet requirements of GMP and pharmacopeial standards (EP, USP, BP, JP, ChP)
Companies that use Nobilus Ent
Customer profileSegments1 record
Ideal customer profiles1 record
Nobilus Ent technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Nobilus Ent partnerships and signals
Strategic signalScale indicators4 records
Recent moves8 records
Expansion highlights5 records
Nobilus Ent competitors and assessment
Company assessmentBroad incumbents
- Recipharm: Swedish-headquartered CDMO offering both API and finished drug product manufacturing across multiple European sites. Directly comparable in the integrated European API plus drug product CDMO model, but with substantially greater scale and breadth.
- Divis Laboratories: India-headquartered API manufacturer producing both synthetic APIs and fermentation-derived ingredients. Comparable in the small-molecule API manufacturing model with multi-pharmacopeial compliance, though much larger and lower-cost.
- Aurobindo Pharma: India-based vertically integrated generic pharmaceutical manufacturer producing APIs and finished dosage forms. Overlaps with Nobilus Ent in synthetic generic API manufacturing (clozapine, flutamide) and finished non-sterile drug products, at significantly larger scale.
- Corden Pharma: International CDMO providing API manufacturing, drug product services, and specialized packaging. Comparable in the integrated contract manufacturing offering and the niche specialty in complex/plant-derived APIs.
- Cambrex: US-headquartered small-molecule API CDMO with multiple manufacturing sites. Comparable in the small-molecule API contract manufacturing business and regulatory positioning, though at much larger scale and broader geographic footprint.
- Siegfried Holding: Swiss-listed CDMO offering both API manufacturing and finished drug product services across multiple sites in Europe and globally. Comparable in the integrated API plus drug product CDMO model, but at much larger scale and broader technology scope.
Direct peers
- Hovione: Portugal-headquartered CDMO specializing in small-molecule API synthesis and drug product manufacturing. Closely comparable as a mid-sized, privately held European API and drug product contract manufacturer serving innovator and generic pharma customers.
- Alchem International: India-headquartered manufacturer specializing in botanical and plant-derived APIs including cardiac glycosides (digoxin) and escin-type saponins. Most directly comparable as a niche producer of plant-derived APIs at GMP grade with multi-pharmacopeial compliance.
Emerging players
- Aesica Pharmaceuticals: European-focused CDMO offering API manufacturing and finished drug product services, particularly in niche and complex molecules. Comparable as a mid-tier European contract manufacturer with similar scale and customer profile.
Regional players
- Polpharma: One of the largest Polish pharmaceutical manufacturers, producing APIs and finished drug products. Most directly comparable in geographic and regulatory context, though significantly larger in scale; both serve as Polish-based pharmaceutical manufacturing hubs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Nobilus Ent social profiles
Digital presenceNobilus Ent compliance and trust
Trust signalCompliance2 records
Nobilus Ent financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nobilus Ent leadership team
Management profileNumber of profiles
Nobilus Ent funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nobilus Ent M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nobilus Ent
What does Nobilus Ent do?
Nobilus Ent manufactures active pharmaceutical ingredients (APIs) through synthesis and isolation from plant materials (horse chestnut and wooly foxglove), and performs contract manufacturing of non-sterile finished drug products (hard capsules, liquid forms, semi-solid forms). The company operates two GMP-certified divisions in Poland serving pharmaceutical companies with custom synthesis, encapsulation, specialized packaging, and impurity reference standards.
Is Nobilus Ent a public or private company?
Nobilus Ent is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Nobilus Ent founded?
Nobilus Ent was founded in 1990. It employs 11 to 50 people.
Where is Nobilus Ent based?
Nobilus Ent is headquartered in Jabłonna, Poland, in the Europe region.
How does Nobilus Ent make money?
Three revenue lines are on record. Contract Manufacturing of APIs are the primary driver. The others are contract Manufacturing of Finished Drug Products and impurity Reference Standards.
Who are Nobilus Ent's main competitors?
Broad incumbents on record are Recipharm, Divis Laboratories, Aurobindo Pharma, Corden Pharma, Cambrex and Siegfried Holding. Direct peers are Hovione and Alchem International. Aesica Pharmaceuticals is listed as an emerging player. Polpharma is listed as a regional player.
Does Nobilus Ent have an API?
No public API is recorded for Nobilus Ent.
What industry is Nobilus Ent in?
Nobilus Ent's product category is Pharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAGAHAB, Small-Molecule API Commercial Manufacturing, with a secondary code of HLAGAHAA, Small-Molecule API Process Development & Route Scouting. Its NAICS code is 3254 and its SIC code is 2833.